|1.||Hasumi, Keiji: 13 articles (11/2015 - 09/2010)|
|2.||Honda, Kazuo: 5 articles (02/2014 - 09/2010)|
|3.||Suzuki, Eriko: 4 articles (11/2015 - 02/2014)|
|4.||Shibata, Keita: 4 articles (01/2014 - 09/2010)|
|5.||Hashimoto, Terumasa: 4 articles (01/2014 - 09/2010)|
|6.||Narasaki, Ritsuko: 3 articles (06/2014 - 01/2012)|
|7.||Nishimura, Naoko: 3 articles (02/2014 - 01/2012)|
|8.||Matsumoto, Naoki: 2 articles (11/2015 - 12/2014)|
|9.||Fujimura, Miki: 2 articles (08/2014 - 10/2011)|
|10.||Tominaga, Teiji: 2 articles (08/2014 - 10/2011)|
02/01/2014 - "In conclusion, SMTP-7 is effective in treating thrombotic stroke in monkeys. "
02/01/2014 - "SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates."
01/01/2014 - "The present study compares gene expression and infarct area in a mouse model of embolic stroke after thrombolysis with t-PA and SMTP-7. "
06/01/2014 - "SMTP-7 has excellent therapeutic activities against thrombotic stroke in several rodent models. "
02/01/2014 - "SMTP-7 is thus a promising candidate for the development of alternative therapy for ischemic stroke. "
09/01/2010 - "Infarction area, neurological score, edema percentage, and regional cerebral blood flow (CBF) were determined as the index of the efficacy of SMTP-7. "
09/01/2010 - "SMTP-7 (0.1, 1, 10 mg/kg) dose dependently reduced infarction area, neurological score, and edema percentage. "
10/03/2011 - "Previous study demonstrated that SMTP-7 further ameliorated infarction volume in a mouse embolic stroke model compared with tissue type plasminogen activator (tPA), but the reason SMTP-7 has more beneficial effect than tPA has not yet been determined. "
|3.||IGA Glomerulonephritis (IGA Nephropathy)
07/01/2012 - "SMTP-7, one of the most potent congeners, is effective in treating thrombotic cerebral infarction. "
07/01/2011 - "Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice."
09/01/2010 - "A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice."
04/01/2011 - "Relatively mild cerebrovascular inflammation and cerebral infarction in the SMTP-7 mice, compared with in rt-PA mice, is thought to be caused at least in part by direct antioxidative actions of SMTP-7 in ECs."
02/01/2014 - "SMTP-7 (Stachybotrys microspora triprenyl phenol-7), a small molecule that promotes plasminogen activation through the modulation of plasminogen conformation, has excellent therapeutic activity against cerebral infarction in several rodent models. "
12/26/2014 - "The small molecule thrombolytic SMTP-7 effectively treats ischemic stroke in several animal models with reducing cerebral hemorrhage. "
02/01/2014 - "SMTP-7 (10 mg/kg, intravenous infusion) significantly increased the postinfusion MCA recanalization rate (32.5-fold, P=0.043) and ameliorated the post-24-h neurologic deficit (by 29%, P=0.02), cerebral infarct (by 46%, P=0.033), and cerebral hemorrhage (by 51%, P=0.013) compared with the vehicle control animals. "
|5.||Tissue Plasminogen Activator (Alteplase)
|6.||Phenol (Carbolic Acid)
|8.||Messenger RNA (mRNA)
|9.||Plasminogen Activators (Plasminogen Activator)